|
|
|
|||||||
|
|||||||||
J. Biol. Chem., Vol. 278, Issue 33, 30413-30416, August 15, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Minireview
Glyceroneogenesis and the Triglyceride/Fatty Acid Cycle*
¶ ¶ ¶ **
From the
Department of Biochemistry, Hebrew
University-Hadassah Medical School, Jerusalem 91120, Israel, the
Department of Biochemistry, Case Western Reserve
University School of Medicine, Cleveland, Ohio 44106-4935, the
¶Schwartz Center for Metabolism and Nutrition,
MetroHealth Center, Cleveland, Ohio 44109, and the
||Department of Molecular Biology, Princeton
University, Princeton, New Jersey 08544
 |
INTRODUCTION |
|---|
During fasting in all mammals, triglyceride stored in adipose tissue is hydrolyzed by a hormone-sensitive lipase to produce free fatty acids (FFA)1 and glycerol. Detailed studies of the balance of glycerol and FFA released from white adipose tissue (WAT) during starvation have noted considerable re-esterification of the FFA in adipose tissue during periods of active lipolysis. For example, in rats fasted for 24 h, about 30% of the FFA is recycled back to triglyceride in WAT (1). In humans, the recycling in this tissue has been estimated to be as high as 40% (2). The recycling of FFA also occurs in the liver as part of a triglyceride/fatty acid cycle that accounts for a considerable quantity of fatty acid recycling. Thus the triglyceride/fatty acid cycle includes local intracellular cycling within the adipose tissue and extracellular or systemic recycling, i.e. the formation of triglycerides in the liver and possibly skeletal muscle (Fig. 1). Almost 30 years ago, Newsholme and Crabtree (3) discussed the importance of this cycle in metabolic regulation and heat production. Quantitative estimates of the triglyceride/fatty acid cycle in human adults and newborn infants and studies in animals show that only a small fraction of the FFA released as a result of lipolysis in the WAT are oxidized, and the majority are re-esterified to triglycerides in various tissues (2–9). The quantitative estimates of triglyceride/fatty acid cycling vary in different studies in humans, depending upon the methodology employed. Intracellular recycling (primarily fatty acid re-esterification in WAT) appears to represent
20–30% of the total, whereas non-adipose
tissue recycling (primarily hepatic) accounts for 50% of
re-esterification of fatty acids in healthy adults after an overnight fast
(Table I). It is important to
note that the fraction of FFA released (lipolysis) that is recycled back to
triglyceride remains relatively constant (75%), despite marked changes in
the rate of total triglyceride/fatty acid cycling during different metabolic
states (Table I). The metabolic
significance of this fixed fractional rate of triglyceride/fatty acid
recycling remains to be determined. However, it is clear that
triglyceride/fatty acid recycling requires the constant generation of glycerol
3-phosphate for triglyceride synthesis, particularly in situations when
cycling is increased.
|
|
Quantitative changes in the triglyceride/fatty acid cycle have been related
to the increased thermogenesis after burns in humans
(4), the increased metabolic
rate of cachectic patients with esophageal cancer
(5), and increased oxygen
consumption following leptin administration
(6),and to the amplification of
substrate flux during acute exercise
(7). In addition,
triglyceride/fatty acid cycle flux is markedly increased following an 87-h
fast in humans (8). Data from
studies using healthy human newborn infants have also shown that 75% of the
fatty acids released by lipolysis are recycled back to triglycerides
(9). In undernourished,
intrauterine growth-retarded infants, higher rates of fatty acid oxidation
were associated with an increased rate of lipolysis and fatty acid cycling, so
that the magnitude of recycling (76%) was similar to that in normal
infants.
What is the metabolic source of glyceride-glycerol needed to support the triglyceride/fatty acid cycle? There are three major possibilities: glucose, via glycolysis, glycerol after phosphorylation by glycerol kinase, or the conversion of pyruvate to glyceride-glycerol via a pathway to be discussed, termed glyceroneogenesis.
|
The Role of Glyceroneogenesis in WAT |
|---|
More than 30 years ago we (10, 11) and others (12) described a pathway for the re-esterification of FFA during fasting in WAT that involved the generation of 3-glycerol phosphate from precursors other than glucose. This pathway, termed glyceroneogenesis, is an abbreviated version of gluconeogenesis. Glyceroneogenesis is defined as the conversion of precursors other than glycerol or glucose to 3-glycerol phosphate for the synthesis of glyceride-glycerol. The discovery of this pathway resulted from our finding that WAT contains both pyruvate carboxylase and the cytosolic form of phosphoenolpyruvate carboxykinase (GTP) (EC 4.1.1.32 [EC] ) (PEPCK-C) (10), two enzymes thought at the time to be involved only in gluconeogenesis. In addition, glyceroneogenesis was predicted to be important in lipid metabolism in ruminants (13), because these animals do not derive glucose from the digestion of dietary carbohydrate, because of the activity of rumen microflora. Rather, they rely on the synthesis of glucose by hepatic and renal gluconeogenesis; thus glucose is at a premium in all ruminants, especially during pregnancy and lactation (14). On this basis, we sought an alternative pathway for the generation of the 3-glycerol phosphate that is required for triglyceride synthesis during fasting in ruminant animals. In fact, in all mammals glucose is a critical fuel for the metabolism of a number of tissues, such as the brain and red blood cells. Thus the importance of an alternative source of 3-glycerol phosphate during fasting, other than glucose, is evident.
In the initial studies that established the existence of the pathway of
glyceroneogenesis, we demonstrated that the addition of pyruvate to rat
epididymal adipose tissue, incubated in vitro, reduced FFA release by
65%, while not altering lipolysis (as determined by the amount of
glycerol released into the medium) because of increased FFA re-esterification
(11,
15,
16). These findings suggested
a potential physiological role for glyceroneogenesis in the re-esterification
of FFA in WAT during fasting, thereby controlling both the release of FFA and
subsequently ketogenesis (11).
Despite these early studies, the pathway has remained largely ignored
(17) or cited only sparingly
in the literature over the past 35 years. A recent perusal of the archives of
PubMed indicated that only 28 published papers referred to glyceroneogenesis
in their titles; the subject has yet to be introduced into text books of
general biochemistry.
This situation has slowly changed over the past several years (18) due in part to the availability of genetically modified mice in which the gene for PEPCK-C has been either specifically deleted (19, 20) or overexpressed in adipose tissue (21). Modifying the expression of the gene for PEPCK-C is critical because this enzyme, which catalyzes the synthesis of phosphoenolpyruvate from oxalacetate, is generally considered to be the pace-setting step in both gluconeogenesis and glyceroneogenesis. PEPCK-C is encoded by a single copy gene, which is expressed to the greatest extent in the liver and kidney cortex and both WAT and brown adipose tissue (BAT). Both the activity of PEPCK-C and the number of enzyme molecules is acutely regulated by alterations in the rate of transcription of the PEPCK-C gene (22), in response to various dietary, hormonal, and environmental stimuli.
The tissue-specific expression of the gene for PEPCK-C is due to regulatory
elements in the gene promoter that bind tissue-specific transcription
activators to direct its expression
(22). Because deletion of the
gene for PEPCK-C is neonatal lethal
(19), we have generated a
targeted mutation in embryonic stem cells of the PPAR
2 binding site in
the promoter of the PEPCK-C gene in mice to assess the role of this enzyme in
adipose tissue in vivo
(20). The PPAR2 binding
site is required for the adipose tissue-specific expression of the gene
(23). The mutation abolished
PEPCK-C gene expression only in WAT and to a smaller extent (50%) in BAT of
the homozygous descendent mice
(PEPCK-PPARE–/– mice). The
mutation virtually abolished glyceroneogenesis in WAT of
PEPCK-PPARE–/– mice, as
determined by their inability to synthesize glyceride-glycerol from pyruvate;
this establishes PEPCK-C as a key enzyme in glyceroneogenesis. The
PEPCK-PPARE–/– mice also lost
considerable triglyceride from their adipose tissue, and about 30% of the
animals became lipodystrophic as adults
(20). The lipodystrophy noted
in the PEPCK-PPARE–/– mice
differs considerably from that found in other models of this disorder
(24) because the animals do
not have altered glucose metabolism, except for a very moderate hyperglycemia
noted in older mice.
Further support for the importance of glyceroneogenesis in adipose tissue was provided by the experiments of Franckhauser et al. (21) who overexpressed a chimeric transgene containing the PEPCK-C structural gene linked to the aP2 promoter in transgenic mice. The gene was expressed at high levels, specifically in WAT because of the specificity of the aP2 gene promoter. Adult transgenic mice had greatly enhanced rates of glyceroneogenesis and higher levels of triglyceride synthesis in their WAT; the animals were also markedly obese and did not exhibit signs of altered glucose metabolism. These findings, together with those of Olswang et al. (20), provide strong support for the pathway of glyceroneogenesis in WAT and the key role that is played by PEPCK-C in controlling the turnover of triglyceride during fasting.
More recently an analysis of 16,757 genes in Caenorhabditis elegans using the RNA-mediated interference technique indicated that disruption of the gene for PEPCK results in a reduced or disorganized pattern of fat deposition in the worm (25).
The importance of glyceroneogenesis in controlling triglyceride turnover in WAT is supported by other lines of evidence. Glucose is the major precursor of 3-glycerol phosphate for triglyceride synthesis in this tissue in the fed state. During diabetes, there is both an elevated level of lipolysis and a greatly diminished rate of transport of glucose into the adipocyte, resulting in mobilization of triglyceride from adipose tissue. Adipocyte-specific deletion of the gene for the transporter that is required for glucose entry into the adipocyte (GLUT4) generated mice that were insulin-resistant. Despite this, these mice did not have a loss of triglycerides from WAT (26). Thus, there must be an alternative source of 3-glycerol phosphate for triglyceride synthesis in WAT in the GLUT4-deficient mice. It is likely that these mice will have an enhanced activity of glyceroneogenesis in their WAT in order to maintain triglyceride homeostasis.
Finally, it is of interest that the gene for the mitochondrial
dicarboxylate transporter is highly expressed in WAT and the level of its mRNA
is induced by fatty acids and inhibited by insulin
(27). The dicarboxylate
transporter is required for the movement of malate in exchange for other
anions, such as 
-ketoglutarate, from the mitochondria to the cytosol.
This pathway would provide the major route for the generation of cytosolic
oxalacetate, a substrate of PEPCK-C in glyceroneogenesis.
|
Glyceroneogenesis in Brown Adipose Tissue |
|---|
It has been known for many years that BAT contains considerable activity of PEPCK-C (about 10 times that of WAT) (28) yet the physiological function of the enzyme in that tissue has not been formally established. The activity of PEPCK-C can be induced in BAT by corticosteroids (29), by the administration of norepinephrine (30) and thyroid hormone (31), by a diet high in protein and devoid of carbohydrate (30) and can be inhibited by insulin (31). Brito et al. (32), using isotopic tracers, have shown that feeding rats a high protein, carbohydrate-free diet will markedly induce the level of glyceroneogenesis from alanine, pyruvate, and lactate in BAT and increase the activity of PEPCK-C 4-fold, leading to increased re-esterification of FFA. This pathway may play a critical role in determining the rate of delivery of fatty acids to the mitochondria for energy generation required for nonshivering thermogenesis. In support of this concept, a high protein, carbohydrate-free diet also reduces the thermogenic capacity of BAT in rats (33). Taken together, these findings suggest that glyceroneogenesis plays a critical role in thermogenesis in BAT by controlling the rate of formation of 3-glycerol phosphate required for triglyceride synthesis in that tissue. There is one surprising aspect of this story; unlike WAT, BAT has considerable activity of glycerol kinase that can form the 3-glycerol phosphate for triglyceride synthesis directly from glycerol. However, most of the preformed fatty acids are re-esterified to triglyceride using 3-glycerol phosphate generated via glyceroneogenesis (32). It is also likely that in these mice fed a carbohydrate-free diet, glyceroneogenesis plays a key role in providing the 3-glycerol phosphate required to ensure triglyceride synthesis from dietary fatty acids in BAT during the fed state. Glyceroneogenesis is, of course, also critical in controlling the rate of triglyceride re-esterification after norepinephrine stimulation due to cold exposure. In this regard, Feldman and Hirst (29) reported that exposing rats to the cold caused a marked decrease in PEPCK-C in BAT. This would mean a decrease in the rate of FFA re-esterification and an increase in the delivery of fatty acid to the mitochondria to maintain thermogenesis.
In a review published in 1975, Hahn and Novak
(28) point out that although
BAT has 10 times the activity of PEPCK-C as compared with WAT (based on
cellular protein content) the rate of glyceroneogenesis, as measured by the
rate of incorporation of labeled pyruvate into triglyceride, is 4 times
greater in WAT than in BAT. They proposed that the "extra" PEPCK-C
activity is involved in a futile cycle in which the enzyme uses the GTP
generated in the citric acid cycle by succinyl-CoA synthase to form
phosphoenolpyruvate from oxalacetate, which is then converted to pyruvate via
pyruvate kinase. Further, the pyruvate is carboxylated to oxalacetate or
decarboxylated to acetyl-CoA to replenish the citric acid cycle. The forward
progress of the citric acid cycle will generate malate that leaves the
mitochondria to maintain the supply of cytosolic oxalacetate for PEPCK-C. The
net result is a futile cycle in which one molecule of GTP is used by PEPCK-C
and one molecule of ATP by pyruvate carboxylase, with only one molecule of ATP
being generated by pyruvate kinase. This proposed futile cycle could aid in
the generation of heat by the BAT. The ablation of expression of the gene for
PEPCK-C in BAT should result in a lower rate of futile cycling of pyruvate as
well as a decrease of triglyceride fatty acid cycling leading to a decrease of
triglyceride in the tissue. This was confirmed in the mouse model in which the
PPAR binding site in the PEPCK-C gene promoter was mutated, thereby
ablating expression of the gene in WAT and BAT (but in no other tissue); the
mice had a marked loss of triglyceride from both tissues
(20). Thus, glyceroneogenesis
in BAT is quantitatively important for maintaining the appropriate level of
triglycerides in the cell. Because fatty acid re-esterification is itself a
futile cycle (6 molecules of ATP are required to activate 3 molecules of fatty
acid to 3 acyl-CoAs for triglyceride synthesis), active rates of triglyceride
synthesis in BAT could add to the heat production generated by fatty
acid-induced uncoupling via UCP-1.
|
Can Glycerol Be Used Directly for the Synthesis of Glyceride-Glycerol? |
|---|
A central premise of WAT metabolism is that the glycerol released during lipolysis cannot be phosphorylated and used for triglyceride synthesis because this tissue has a negligible activity of glycerol kinase. Most of the glycerol released during fasting is taken up by the liver and converted to glucose, although some glycerol can be used by BAT (28) and muscle (34, 35). Because some FFA is re-esterified back to triglyceride by WAT during fasting, the rate of glycerol release by that tissue is routinely used as a measure of lipolysis. Over the years there have been several reports of glycerol kinase activity in WAT, but the reported activity is not great enough to support the high rates of FFA re-esterification that would be required for triglyceride synthesis when glucose is limiting, such as occurs in this tissue during fasting. Recently, Guan et al. (17) proposed that WAT contains sufficient glycerol kinase to play a role in triglyceride homeostasis in this tissue in the presence of thiazolidinediones. As predicted, they detected very low levels of glycerol kinase in control adipocytes but upon the addition of concentrations of 0.1 µM (or higher) of rosiglitazone, they noted the presence of glycerol kinase activity. In addition, the injection of ciglitazone (100 mg/kg of body weight/day for 4 days) to Ob/Ob mice caused an induction of glycerol kinase in the WAT of the animals. Interestingly, non-obese mice had far less glycerol kinase induction after ciglitazone injection, and control animals had negligible levels of glycerol kinase in their adipose tissue. Adipocytes responded to the addition of rosiglitazone by greatly increasing the incorporation of isotopically labeled glycerol into glyceride-glycerol and by reducing FFA release (after 48 h of rosiglitazone treatment). We can conclude from this study that the thiazolidinediones can induce the expression of the gene for glycerol kinase in WAT and can thus stimulate FFA re-esterification in that tissue. However, the levels of glycerol kinase in WAT are negligible in basal, unstimulated conditions.
Thiazolidinediones are ligands for PPAR, a member of the steroid
hormone/thyroid hormone/retinoid receptor superfamily of transcription
factors. PPAR causes the marked and rapid induction of PEPCK-C gene
expression in WAT (36) and has
been shown to bind to specific sites in the PEPCK-C gene promoter
(36–38).
In addition, PPAR is required for the tissue-specific expression of the
gene for PEPCK-C in WAT (23).
Thus the administration of thiazolidinediones would stimulate transcription of
the gene for PEPCK-C (39), as
well as the gene for glycerol kinase, suggesting that the increase in FFA
re-esterification noted by Guan et al.
(17) could be due as well to
the thiazolidinedione induction of PEPCK-C gene transcription
(18,
39), which in turn would be
accompanied by an increase in glyceroneogenesis.
The relative importance of glyceroneogenesis versus glycerol kinase in the thiazolidinedione-induced decrease in the release of fatty acid from WAT has been evaluated in a recent study by Tordjman et al. (40). They noted that rosiglitazone induced glycerol kinase activity in isolated adipocytes from a very low basal activity of 0.2 nmol/min/mg of protein to 0.5 nmol/min/mg of protein after 72 h. In contrast, the activity of PEPCK-C in adipose tissue was 5 nmol/min/mg of protein in the basal state and 14 nmol/min/mg of protein after the addition of rosiglitazone. The overall rate of fatty acid re-esterification resulting from glyceroneogenesis, as determined in this study, was 3–5 times higher than the rates for glycerol conversion to glyceride-glycerol in adipocytes incubated with rosiglitazone. These authors conclude that the major effect of rosiglitazone in decreasing the levels of plasma FFA is due to a stimulation of PEPCK-C gene transcription leading to an increase in fatty acid re-esterification via glyceroneogenesis and that the induction of glycerol kinase is a relatively minor component of the response of the WAT to thiazolidinediones (40).
|
Glyceroneogenesis Occurs in the Liver |
|---|
 TOPINTRODUCTIONThe Role of Glyceroneogenesis...Glyceroneogenesis in Brown...Can Glycerol Be Used... Glyceroneogenesis Occurs in the... Regulation of Glyceroneogenesis...A Summary RemarkREFERENCES |
|---|
Although glyceroneogenesis was first described in WAT, its function in the liver was not recognized until the work of Botion et al. (41), who reported high rates of glyceroneogenesis in the livers of rats fed a high protein, carbohydrate-free diet. The presence of glyceroneogenesis in the liver was unexpected for two reasons. First, it is not intuitive that the liver would make triglyceride during periods of fasting, when it is actively involved in gluconeogenesis and is using fatty acids from adipose tissue as a source of energy to support this process (and urea synthesis). Second, the liver can readily use the considerable glycerol released from WAT during lipolysis as a source of 3-glycerol phosphate (as mentioned above, the liver has considerable glycerol kinase activity (42)). Glycerol kinase readily phosphorylates glycerol, which should make hepatic glyceroneogenesis redundant. However, experiments by Kalhan et al. (43), using stable isotopes in vivo, demonstrated that glycerol contributed only about 3% of the glyceride-glycerol noted in the triglyceride in the blood of human subjects after an overnight fast. These studies have been extended to include more human subjects under a variety of experimental conditions, such as prolonged fasting and diabetes, and support our original observations.2 Plasma glycerol thus contributes only marginally to the synthesis of glyceride-glycerol of hepatic triglyceride present in plasma very low density lipoprotein, whereas glyceroneogenesis provides about 65% of the glyceride-glycerol. The underlying biochemical mechanisms that regulate the flow of carbon to glyceride-glycerol in the liver during starvation remains to be elucidated.
|
Regulation of Glyceroneogenesis in Liver and WAT |
|---|
|
TOPINTRODUCTIONThe Role of Glyceroneogenesis...Glyceroneogenesis in Brown...Can Glycerol Be Used...Glyceroneogenesis Occurs in the...Regulation of Glyceroneogenesis...A Summary RemarkREFERENCES |
|---|
The data outlined above underline the importance of the coordinate regulation of PEPCK-C gene transcription in the liver and WAT. Active glyceroneogenesis in both liver and WAT requires coordination of triglyceride turnover in the two tissues because PEPCK-C activity catalyzes the rate-limiting step in triglyceride re-esterification in both tissues (glyceroneogenesis). Lipid is released from WAT as FFA and from the liver as triglycerides. Thus, glyceroneogenesis affects lipid metabolism in opposite ways in the two tissues; it restrains FFA release from WAT (11) and enhances it (in the form of triglyceride) from the liver (44). It has been shown in rats that adrenalectomy enhances glyceroneogenesis and diminishes FFA release from adipose tissue in vitro (15, 45). The addition of dexamethasone to cultured hepatocytes increased the synthesis of triglycerides and apolipoproteins E and B and stimulated the release of very low density lipoproteins to the medium (44). How then is lipid homeostasis coordinated between the two tissues? We propose that the reciprocal regulation of PEPCK-C gene transcription by glucocorticoids provides a mechanism for such coordination because it represses PEPCK-C gene transcription in WAT, while enhancing it in the liver.
Several hormones work together to regulate PEPCK-C activity and both gluconeogenesis and glyceroneogenesis (15, 46, 47) and do so in a differential manner in specific tissues that express the enzyme. The best example is the regulation by glucocorticoids that induce PEPCK-C gene transcription in the kidney and liver (48) but repress it in WAT (49). Moreover, the glucocorticoid-mediated repression of PEPCK-C synthesis is effective even under basal concentrations of circulating glucocorticoids, because removal of the adrenals enhances enzyme synthesis by 3-fold (50).
The molecular mechanisms that underlie the reciprocal regulation of PEPCK-C
gene transcription by glucocorticoids are not well understood. This
differential regulation of PEPCK-C gene transcription most likely involves the
interaction of tissue-specific transcriptional activators that results in an
induction of PEPCK-C gene transcription (liver and kidney) or repression
(WAT). We have recently found that members of the C/EBP family of
transcription factors are involved in the repression of PEPCK-C gene
transcription in WAT (51).
DNase I footprint analysis of the rat PEPCK-C gene promoter using nuclear
proteins from adipocytes that had been treated with dexamethasone indicated
that the hormone treatment interfered with the binding of nuclear proteins to
the C/EBP recognition sites in the promoter. Furthermore, PPAR2 and
both C/EBP and C/EBP
activated transcription from the PEPCK-C
gene promoter in NIH3T3 fibroblasts. However, dexamethasone (in the presence
of the glucocorticoid receptor) inhibited the activation of transcription by
members of the C/EBP family but had no effect on PPAR-stimulated transcription
(51). This repression of
transcription of PEPCK-C gene transcription by glucocorticoids does not
require DNA binding of the receptor, suggesting a mechanism of repression that
involves a co-regulatory protein such as CREB-binding protein/p300.
Interestingly, mice that are homozygous for a deletion in the gene for
C/EBP have 4 times the concentration of PEPCK-C mRNA and twice the
activity of the enzyme in WAT as compared with control
littermates.3 These
findings suggest that C/EBP is important for the negative control of
PEPCK-C gene transcription in WAT. The relative importance of the various
transcription factors that control PEPCK-C gene transcription in the liver and
WAT remains to be determined. Despite the progress made in the elucidation of
the reciprocal hormonal control of PEPCK-C gene transcription in various
tissues, its physiological meaning remained an enigma until recent metabolic
studies indicated the presence of active hepatic glyceroneogenesis
(41,
43).
|
A Summary Remark |
|---|
The ability to genetically manipulate animals has made a major impact on our understanding of metabolic processes. The pathway of glyceroneogenesis was first described more than 35 years ago with little subsequent interest from the scientific community, despite its potential role in controlling fatty acid recycling in both WAT and liver. Glyceroneogenesis also provides a mechanistic explanation for the findings of Bernard Houssay (52) and of Long and Leukins (53) that glucocorticoids are required for the development of diabetes in animals. Without glucocorticoids the liver will not make as much glucose (due to a lower activity of PEPCK-C) and will not re-esterify fatty acids to triglyceride as readily. WAT will also have higher rates of glyceroneogenesis, resulting in less FFA release. A higher concentration of both glucose and FFA in the blood is a characteristic of diabetes. Thus, glucocorticoids with their coordinating role in controlling expression of the gene for PEPCK-C, both WAT and liver, would be required for the development of diabetes mellitus. Viewed in this way, the physiological significance of PEPCK-C and glyceroneogenesis in WAT and liver can be better understood.
|
FOOTNOTES |
|---|
* This minireview will be reprinted in the 2003 Minireview Compendium, which will be available in January, 2004. The work described in the review was supported by Grants DK-58620 (to R. W. H.) and HD11089 (to S. C. K.) from the National Institutes of Health, by Grant 1999346 from the United States-Israel Binational Foundation (to L. R.), and by a grant from the Israel Ministry of Health. This is the third article of six in the "New Animal Models for Study of Metabolism" Minireview Series.
** To whom correspondence should be addressed. Tel.: 216-368-3880; Fax: 216-368-4544; E-mail: rwh{at}po.cwru.edu.
1 The abbreviations used are: FFA, free fatty acid(s); WAT, white adipose
tissue; BAT, brown adipose tissue; PPAR, peroxisome proliferator-activated
receptor; PPARE, PPAR response element; PEPCK, phosphoenolpyruvate
carboxykinase; C/EBP, CCAAT/enhancer-binding protein; CREB, cAMP-response
element-binding protein.
2 S. C. Kalhan, unpublished results.
3 C. M. Croniger and R. W. Hanson, unpublished results.
|
REFERENCES |
|---|
- Vaughan, M. J. (1962) J. Biol.
Chem. 237,
3354–3358
[Free Full Text] - Jensen, M. D., Ekberg, K., and Landau, B. R. (2001) Am. J. Physiol. 281, E789–E793
- Newsholme, E. A., and Crabtree, B. (1976) Biochem. Soc. Symp. 41, 61–109[Medline] [Order article via Infotrieve]
- Wolfe, R. R., Herndon, D. N., Jahoor, F., Miyoshi, H., and Wolfe, M. (1987) N. Engl. J. Med. 317, 403–408[Abstract]
- Klein, S., and Wolfe, R. R. (1990) J. Clin. Invest. 86, 1403–1408[Medline] [Order article via Infotrieve]
- Reidy, S. P., and Weber, J. M. (2002) Am. J. Physiol. 282, E312–E317
- Bahr, R., Hansson, P., and Sejersted, O. M. (1990) Metabolism 39, 993–999[CrossRef][Medline] [Order article via Infotrieve]
- Elia, M., Zed, C., Neale, G., and Livesey, G. (1987) Metabolism 36, 251–255[CrossRef][Medline] [Order article via Infotrieve]
- Patel, D., and Kalhan, S. (1992) Pediatr. Res. 31, 52–58[Medline] [Order article via Infotrieve]
- Ballard, F. J., Hanson, R. W., and Leveille, G. A.
(1967) J. Biol. Chem.
242,
2746–2750
[Abstract/Free Full Text] - Reshef, L., Hanson, R. W., and Ballard, F. J. (1970)
J. Biol. Chem. 245,
5979–5984
[Abstract/Free Full Text] - Gorin, E., Tal-Or, Z., and Shafrir, E. (1969) Eur. J. Biochem. 8, 370–375[Medline] [Order article via Infotrieve]
- Reshef, L., Niv, J., and Shapiro, B. (1967) J. Lipid Res. 8, 688–691[Abstract]
- Ballard, F. J., Hanson, R. W., and Kronfeld, D. S. (1969) Fed. Proc. 112, 195–202
- Reshef, L., Ballard, F. J., and Hanson, R. W. (1969)
J. Biol. Chem. 244,
5577–5581
[Abstract/Free Full Text] - Reshef, L., Hanson, R. W., and Ballard, F. J. (1969)
J. Biol. Chem. 244,
1994–2001
[Abstract/Free Full Text] - Guan, H. P., Li, Y., Jensen, M. V., Newgard, C. B., Steppan, C. M., and Lazar, M. A. (2002) Nat Med. 8, 1122–1128[CrossRef][Medline] [Order article via Infotrieve]
- Beale, E. G., Hammer, R. E., Antoine, B., and Forest, C.
(2002) FASEB J.
16,
1695–1696
[Abstract/Free Full Text] - She, P., Shiota, M., Shelton, K. D., Chalkley, R., Postic, C., and
Magnuson, M. A. (2000) Mol. Cell. Biol.
20,
6508–6517
[Abstract/Free Full Text] - Olswang, Y., Cohen, H., Papo, O., Cassuto, H., Croniger, C. M.,
Hakimi, P., Tilghman, S. M., Hanson, R. W., and Reshef, L. (2002)
Proc. Natl. Acad. Sci. U. S. A.
99,
625–630
[Abstract/Free Full Text] - Franckhauser, S., Munoz, S., Pujol, A., Casellas, A., Riu, E.,
Otaegui, P., Su, B., and Bosch, F. (2002)
Diabetes 51,
624–630
[Abstract/Free Full Text] - Hanson, R. W., and Reshef, L. (1997) Annu. Rev. Biochem. 66, 581–611[CrossRef][Medline] [Order article via Infotrieve]
- Devine, J. H., Eubank, D. W., Clouthier, D. E., Tontonoz, P.,
Spiegelman, B. M., Hammer, R. E., and Beale, E. G. (1999)
J. Biol. Chem. 274,
13604–13612
[Abstract/Free Full Text] - Reue, K., and Peterfy, M. (2000) Curr. Atheroscler. Rep. 2, 390–396[Medline] [Order article via Infotrieve]
- Ashrafi, K., Chang, F. Y., Watts, J. L., Fraser, A. G., Kamath, R. S., Ahringer, J., and Ruvkun, G. (2003) Nature 421, 268–272[CrossRef][Medline] [Order article via Infotrieve]
- Abel, E. D., Peroni, O., Kim, J. K., Kim, Y. B., Boss, O., Hadro, E., Minnemann, T., Shulman, G. I., and Kahn, B. B. (2001) Nature 409, 729–733[CrossRef][Medline] [Order article via Infotrieve]
- Das, K., Lewis, R. Y., Combatsiaris, T. P., Lin, Y., Shapiro, L., Charron, M. J., and Scherer, P. E. (1999) Biochem. J. 344, 313–320[CrossRef][Medline] [Order article via Infotrieve]
- Hahn, P., and Novak, M. (1975) J. Lipid Res. 16, 79–91[Medline] [Order article via Infotrieve]
- Feldman, D., and Hirst, M. (1978) Am. J. Physiol. 235, E197–E202[Medline] [Order article via Infotrieve]
- Hahn, P., and Kirby, L. T. (1974) Can. J. Biochem. 52, 739–743[Medline] [Order article via Infotrieve]
- Hahn, P., and Hassanali, S. (1982) Biol. Neonate 41, 1–7[Medline] [Order article via Infotrieve]
- Brito, M. N., Brito, N. A., Brito, S. R., Moura, M. A., Kawashita, N. H., Kettelhut, I. C., and Migliorini, R. H. (1999) Am. J. Physiol. 276, R1003–R1009[Medline] [Order article via Infotrieve]
- Brito, M. N., Brito, N. A., and Migliorini, R. H.
(1992) J. Nutr.
122,
2081–2086
[Abstract/Free Full Text] - Previs, S. F., Martin, S. K., Hazey, J. W., Soloviev, M. V., Keating, A. P., Lucas, D., David, F., Koshy, J., Kirschenbaum, D. W., Tserng, K. Y., and Brunengraber, H. (1996) Am. J. Physiol. 271, E1118–E1124[Medline] [Order article via Infotrieve]
- Guo, Z., and Jensen, M. D. (1999) J. Biol.
Chem. 274,
23702–23706
[Abstract/Free Full Text] - Tontonoz, P., Hu, E., Devine, J., Beale, E. G., and Spiegelman, B. M. (1995) Mol. Cell. Biol. 15, 351–357[Abstract]
- Eubank, D. W., Duplus, E., Williams, S. C., Forest, C., and Beale,
E. G. (2001) J. Biol. Chem.
276,
30561–30569
[Abstract/Free Full Text] - Tontonoz, P., Graves, R. A., Budavari, A. I., Erdjument-Bromage,
H., Lui, M., Hu, E., Tempst, P., and Spiegelman, B. M. (1994)
Nucleic Acids Res. 22,
5628–5634
[Abstract/Free Full Text] - Glorian, M., Duplus, E., Beale, E. G., Scott, D. K., Granner, D. K., and Forest, C. (2001) Biochimie (Paris) 83, 933–943
- Tordjman, J., Chauvet, G., Quette, J., Beale, E. G., Forest, C.,
and Antoine, B. (2003) J. Biol. Chem.
278,
18785–18790
[Abstract/Free Full Text] - Botion, L. M., Brito, M. N., Brito, N. A., Brito, S. R., Kettelhut, I. C., and Migliorini, R. H. (1998) Metabolism 47, 1217–1221[CrossRef][Medline] [Order article via Infotrieve]
- Lin, E. C. (1977) Annu. Rev. Biochem. 46, 765–795[CrossRef][Medline] [Order article via Infotrieve]
- Kalhan, S. C., Mahajan, S., Burkett, E., Reshef, L., and Hanson, R.
W. (2001) J. Biol. Chem.
276,
12928–12931
[Abstract/Free Full Text] - Martin-Sanz, P., Vance, J. E., and Brindley, D. N. (1990) Biochem. J. 271, 575–583[Medline] [Order article via Infotrieve]
- Reshef, L., Meyuhas, O., Boshwitz, C., Hanson, R. W., and Ballard, F. J. (1972) Isr. J. Med. Sci. 8, 372–381[Medline] [Order article via Infotrieve]
- Reshef, L., and Hanson, R. W. (1972) Biochem. J. 127, 809–818[Medline] [Order article via Infotrieve]
- Meyuhas, O., Reshef, L., Gunn, J. M., Hanson, R. W., and Ballard, F. J. (1976) Biochem. J. 158, 1–7[Medline] [Order article via Infotrieve]
- Meisner, H., Loose, D. S., and Hanson, R. W. (1985) Biochemistry 24, 421–425[CrossRef][Medline] [Order article via Infotrieve]
- Nechushtan, Benvenisty, N., Brandeis, R., and Reshef, L.
(1987) Nucleic Acids Res.
15,
6405–6417
[Abstract/Free Full Text] - Meyuhas, O., Reshef, L., Ballard, F. J., and Hanson, R. W. (1976) Biochem. J. 158, 9–16[Medline] [Order article via Infotrieve]
- Olswang, Y., Blum, B., Cohen, H., Biberman, Y., Cassuto, H.,
Hanson, R. W., and Reshef, L. (2003) J. Biol.
Chem. 278,
12929–12936
[Abstract/Free Full Text] - Houssay, B. A. (1942)
Endocrinology 30,
884–892
[Abstract/Free Full Text] - Long, C. D. W., and Leukins, F. D. W. (1936) J. Exp. Med. 63, 465–490[Abstract]
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  V. Bezaire, A. Mairal, C. Ribet, C. Lefort, A. Girousse, J. Jocken, J. Laurencikiene, R. Anesia, A.-M. Rodriguez, M. Ryden, et al. Contribution of Adipose Triglyceride Lipase and Hormone-sensitive Lipase to Lipolysis in hMADS Adipocytes J. Biol. Chem., July 3, 2009; 284(27): 18282 - 18291. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-L. Peyot, C. Guay, M. G. Latour, J. Lamontagne, R. Lussier, M. Pineda, N. B. Ruderman, G. Haemmerle, R. Zechner, E. Joly, et al. Adipose Triglyceride Lipase Is Implicated in Fuel- and Non-fuel-stimulated Insulin Secretion J. Biol. Chem., June 19, 2009; 284(25): 16848 - 16859. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Gaidhu, S. Fediuc, N. M. Anthony, M. So, M. Mirpourian, R. L. S. Perry, and R. B. Ceddia Prolonged AICAR-induced AMP-kinase activation promotes energy dissipation in white adipocytes: novel mechanisms integrating HSL and ATGL J. Lipid Res., April 1, 2009; 50(4): 704 - 715. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. R. Bederman, S. Foy, V. Chandramouli, J. C. Alexander, and S. F. Previs Triglyceride Synthesis in Epididymal Adipose Tissue: CONTRIBUTION OF GLUCOSE AND NON-GLUCOSE CARBON SOURCES J. Biol. Chem., March 6, 2009; 284(10): 6101 - 6108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Shi, A. Burkart, S. M. Nicoloro, M. P. Czech, J. Straubhaar, and S. Corvera Paradoxical Effect of Mitochondrial Respiratory Chain Impairment on Insulin Signaling and Glucose Transport in Adipose Cells J. Biol. Chem., November 7, 2008; 283(45): 30658 - 30667. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Nielsen, T. A. Pedersen, D. Hagenbeek, P. Moulos, R. Siersbaek, E. Megens, S. Denissov, M. Borgesen, K.-J. Francoijs, S. Mandrup, et al. Genome-wide profiling of PPAR{gamma}:RXR and RNA polymerase II occupancy reveals temporal activation of distinct metabolic pathways and changes in RXR dimer composition during adipogenesis Genes & Dev., November 1, 2008; 22(21): 2953 - 2967. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. K. Nye, R. W. Hanson, and S. C. Kalhan Glyceroneogenesis Is the Dominant Pathway for Triglyceride Glycerol Synthesis in Vivo in the Rat J. Biol. Chem., October 10, 2008; 283(41): 27565 - 27574. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Prentki and S. R. M. Madiraju Glycerolipid Metabolism and Signaling in Health and Disease Endocr. Rev., October 1, 2008; 29(6): 647 - 676. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Clow, K. V. Ewart, and W. R. Driedzic Low temperature directly activates the initial glycerol antifreeze response in isolated rainbow smelt (Osmerus mordax) liver cells Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2008; 295(3): R961 - R970. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Magnoni, E. Vaillancourt, and J.-M. Weber In vivo regulation of rainbow trout lipolysis by catecholamines J. Exp. Biol., August 1, 2008; 211(15): 2460 - 2466. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-S. Gauthier, H. Miyoshi, S. C. Souza, J. M. Cacicedo, A. K. Saha, A. S. Greenberg, and N. B. Ruderman AMP-activated Protein Kinase Is Activated as a Consequence of Lipolysis in the Adipocyte: POTENTIAL MECHANISM AND PHYSIOLOGICAL RELEVANCE J. Biol. Chem., June 13, 2008; 283(24): 16514 - 16524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Holness Leptin: A Central Role in an Expanding Answer to Weight Loss Endocrinology, December 1, 2007; 148(12): 5601 - 5603. [Full Text] [PDF]
|
|
|
|
|
|
P. Hakimi, J. Yang, G. Casadesus, D. Massillon, F. Tolentino-Silva, C. K. Nye, M. E. Cabrera, D. R. Hagen, C. B. Utter, Y. Baghdy, et al. Overexpression of the Cytosolic Form of Phosphoenolpyruvate Carboxykinase (GTP) in Skeletal Muscle Repatterns Energy Metabolism in the Mouse J. Biol. Chem., November 9, 2007; 282(45): 32844 - 32855. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. S. Martins-Santos, V. E. Chaves, D. Frasson, R. P. Boschini, M. A. R. Garofalo, I. d. C. Kettelhut, and R. H. Migliorini Glyceroneogenesis and the supply of glycerol-3-phosphate for glyceride-glycerol synthesis in liver slices of fasted and diabetic rats Am J Physiol Endocrinol Metab, November 1, 2007; 293(5): E1352 - E1357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. I. Anghel, E. Bedu, C. D. Vivier, P. Descombes, B. Desvergne, and W. Wahli Adipose Tissue Integrity as a Prerequisite for Systemic Energy Balance: A CRITICAL ROLE FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR {gamma} J. Biol. Chem., October 12, 2007; 282(41): 29946 - 29957. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Ceperuelo-Mallafre, M. Miranda, M. R. Chacon, N. Vilarrasa, A. Megia, C. Gutierrez, J. M. Fernandez-Real, J. M. Gomez, E. Caubet, G. Fruhbeck, et al. Adipose Tissue Expression of the Glycerol Channel Aquaporin-7 Gene Is Altered in Severe Obesity But Not in Type 2 Diabetes J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3640 - 3645. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Tordjman, S. Leroyer, G. Chauvet, J. Quette, C. Chauvet, C. Tomkiewicz, C. Chapron, R. Barouki, C. Forest, M. Aggerbeck, et al. Cytosolic Aspartate Aminotransferase, a New Partner in Adipocyte Glyceroneogenesis and an Atypical Target of Thiazolidinedione J. Biol. Chem., August 10, 2007; 282(32): 23591 - 23602. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Michailidou, A. P Coll, C. J Kenyon, N. M Morton, S. O'Rahilly, J. R Seckl, and K. E Chapman Peripheral mechanisms contributing to the glucocorticoid hypersensitivity in proopiomelanocortin null mice treated with corticosterone J. Endocrinol., July 1, 2007; 194(1): 161 - 170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Yan, Z. Gao, G. Yu, Q. He, J. Weng, and J. Ye Nuclear Corepressor Is Required for Inhibition of Phosphoenolpyruvate Carboxykinase Expression by Tumor Necrosis Factor-{alpha} Mol. Endocrinol., July 1, 2007; 21(7): 1630 - 1641. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Okamura, H. Shimizu, T. Nagao, R. Ueda, and S. Ishii ATF-2 Regulates Fat Metabolism in Drosophila Mol. Biol. Cell, April 1, 2007; 18(4): 1519 - 1529. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Lobo, B. M. Wiczer, A. J. Smith, A. M. Hall, and D. A. Bernlohr Fatty acid metabolism in adipocytes: functional analysis of fatty acid transport proteins 1 and 4 J. Lipid Res., March 1, 2007; 48(3): 609 - 620. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Jurczak, A. M. Danos, V. R. Rehrmann, M. B. Allison, C. C. Greenberg, and M. J. Brady Transgenic overexpression of protein targeting to glycogen markedly increases adipocytic glycogen storage in mice Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E952 - E963. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Kresge, R. D. Simoni, and R. L. Hill The Discovery of the Glyceroneogenic Pathway: the Work of Richard Hanson J. Biol. Chem., February 23, 2007; 282(8): e6 - e6. [Full Text] [PDF]
|
|
|
|
 |
|
 V. E. Chaves, D. Frasson, M. E. S. Martins-Santos, R. P. Boschini, M. A. R. Garofalo, W. T. L. Festuccia, I. C. Kettelhut, and R. H. Migliorini Glyceroneogenesis Is Reduced and Glucose Uptake Is Increased in Adipose Tissue from Cafeteria Diet-Fed Rats Independently of Tissue Sympathetic Innervation J. Nutr., October 1, 2006; 136(10): 2475 - 2480. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. N. Leroyer, J. Tordjman, G. Chauvet, J. Quette, C. Chapron, C. Forest, and B. Antoine Rosiglitazone Controls Fatty Acid Cycling in Human Adipose Tissue by Means of Glyceroneogenesis and Glycerol Phosphorylation J. Biol. Chem., May 12, 2006; 281(19): 13141 - 13149. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Murphy Stable isotope methods for the in vivo measurement of lipogenesis and triglyceride metabolism J Anim Sci, April 1, 2006; 84(13_suppl): E94 - E. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Cassuto, K. Kochan, K. Chakravarty, H. Cohen, B. Blum, Y. Olswang, P. Hakimi, C. Xu, D. Massillon, R. W. Hanson, et al. Glucocorticoids Regulate Transcription of the Gene for Phosphoenolpyruvate Carboxykinase in the Liver via an Extended Glucocorticoid Regulatory Unit J. Biol. Chem., October 7, 2005; 280(40): 33873 - 33884. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. A. MacDougald and C. F. Burant Obesity and metabolic perturbations after loss of aquaporin 7, the adipose glycerol transporter PNAS, August 2, 2005; 102(31): 10759 - 10760. [Full Text] [PDF]
|
|
|
|
|
|
S. Jitrapakdee, M. Slawik, G. Medina-Gomez, M. Campbell, J. C. Wallace, J. K. Sethi, S. O'Rahilly, and A. J. Vidal-Puig The Peroxisome Proliferator-activated Receptor-{gamma} Regulates Murine Pyruvate Carboxylase Gene Expression in Vivo and in Vitro J. Biol. Chem., July 22, 2005; 280(29): 27466 - 27476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Chen, E. Peacock, W. Samady, S. M. Turner, R. A. Neese, M. K. Hellerstein, and E. J. Murphy Physiologic and Pharmacologic Factors Influencing Glyceroneogenic Contribution to Triacylglyceride Glycerol Measured by Mass Isotopomer Distribution Analysis J. Biol. Chem., July 8, 2005; 280(27): 25396 - 25402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Nishi, H. Hiejima, H. Hosoda, H. Kaiya, K. Mori, Y. Fukue, T. Yanase, H. Nawata, K. Kangawa, and M. Kojima Ingested Medium-Chain Fatty Acids Are Directly Utilized for the Acyl Modification of Ghrelin Endocrinology, May 1, 2005; 146(5): 2255 - 2264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-P. Guan, T. Ishizuka, P. C. Chui, M. Lehrke, and M. A. Lazar Corepressors selectively control the transcriptional activity of PPAR{gamma} in adipocytes Genes & Dev., February 15, 2005; 19(4): 453 - 461. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Lin, A. H. Berg, P. Iyengar, T. K. T. Lam, A. Giacca, T. P. Combs, M. W. Rajala, X. Du, B. Rollman, W. Li, et al. The Hyperglycemia-induced Inflammatory Response in Adipocytes: THE ROLE OF REACTIVE OXYGEN SPECIES J. Biol. Chem., February 11, 2005; 280(6): 4617 - 4626. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. W. Hanson Metabolism in the Era of Molecular Biology J. Biol. Chem., January 21, 2005; 280(3): 1705 - 1715. [Full Text] [PDF]
|
|
|
|
|
|
S. C. Burgess, N. Hausler, M. Merritt, F. M. H. Jeffrey, C. Storey, A. Milde, S. Koshy, J. Lindner, M. A. Magnuson, C. R. Malloy, et al. Impaired Tricarboxylic Acid Cycle Activity in Mouse Livers Lacking Cytosolic Phosphoenolpyruvate Carboxykinase J. Biol. Chem., November 19, 2004; 279(47): 48941 - 48949. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Jenkins, D. J. Mancuso, W. Yan, H. F. Sims, B. Gibson, and R. W. Gross Identification, Cloning, Expression, and Purification of Three Novel Human Calcium-independent Phospholipase A2 Family Members Possessing Triacylglycerol Lipase and Acylglycerol Transacylase Activities J. Biol. Chem., November 19, 2004; 279(47): 48968 - 48975. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Bogacka, H. Xie, G. A. Bray, and S. R. Smith The Effect of Pioglitazone on Peroxisome Proliferator-Activated Receptor-{gamma} Target Genes Related to Lipid Storage In Vivo Diabetes Care, July 1, 2004; 27(7): 1660 - 1667. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Faraj and K. Cianflone Differential regulation of fatty acid trapping in mouse adipose tissue and muscle by ASP Am J Physiol Endocrinol Metab, July 1, 2004; 287(1): E150 - E159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Y. Hui, S. S. Sheth, J. M. Diffley, D. W. Potter, A. J. Lusis, A. D. Attie, and R. A. Davis Mice Lacking Thioredoxin-interacting Protein Provide Evidence Linking Cellular Redox State to Appropriate Response to Nutritional Signals J. Biol. Chem., June 4, 2004; 279(23): 24387 - 24393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Okamoto and D. Accili In Vivo Mutagenesis of the Insulin Receptor J. Biol. Chem., August 1, 2003; 278(31): 28359 - 28362. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |